Joel Palefsky, M.D., C.M., F.R.C.P.(C).  Emeritus Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine.   He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the founder of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center.   He is the protocol chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study that showed that treatment of anal cancer precursor lesions prevents the development of anal cancer. He leads the effort to analyze ANCHOR Biorepository specimens to develop novel testing algorithms for anal cancer screening, identify new biomarkers of progression and regression of anal cancer precursor lesions, and elucidate the molecular pathogenesis of anal cancer. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society.  He is founder and chairman of the International Papillomavirus Society International HPV Awareness campaign.